

Rp Hall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1255048/publications.pdf>

Version: 2024-02-01

41
papers

3,050
citations

471509

17
h-index

345221

36
g-index

42
all docs

42
docs citations

42
times ranked

3924
citing authors

#	ARTICLE	IF	CITATIONS
1	Training Physicianâ€™Scientists: A Call for a Cultural Shift in Our Approach. JID Innovations, 2022, 2, 100093.	2.4	2
2	How Do Experts Treat Patients with Bullousâ€™Pemphigoid around the World? Anâ€™International Survey. JID Innovations, 2022, 2, 100129.	2.4	2
3	Regulatory B10 Cells Increase after Rituximab Therapy but Not after Conventional Immunosuppression in Patients with Pemphigus. Journal of Investigative Dermatology, 2021, 141, 443-446.	0.7	1
4	Quantifying Skin Stiffness in Graft-Versus-Host Disease, Morphea, and Systemic Sclerosis Using Acoustic Radiation Force Impulse Imaging and Shear Wave Elastography. Journal of Investigative Dermatology, 2021, 141, 924-927.e2.	0.7	10
5	Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus. Journal of Investigative Dermatology, 2021, 141, 2858-2865.e4.	0.7	24
6	Diagnosis and management of pemphigus: Recommendations of an international panel of experts. Journal of the American Academy of Dermatology, 2020, 82, 575-585.e1.	1.2	224
7	JID Innovations: Skin Science from Molecules to Population Health. Journal of Investigative Dermatology, 2020, 140, 1672-1673.	0.7	0
8	Correlation of IgG autoantibodies against acetylcholine receptors and desmogleins in patients with pemphigus treated with steroid sparing agents or rituximab. PLoS ONE, 2020, 15, e0233957.	2.5	6
9	Anetoderma Associated With a Succinate Dehydrogenase Gene Mutation. JAMA Dermatology, 2019, 155, 1317.	4.1	5
10	Inpatient Management of Autoimmune Blistering Diseases: an Update, Review, and Practical Guide. Current Dermatology Reports, 2019, 8, 208-218.	2.1	2
11	Induction of hair follicle neogenesis with cultured mouse dermal papilla cells in de novo regenerated skin tissues. Journal of Tissue Engineering and Regenerative Medicine, 2019, 13, 1641-1650.	2.7	12
12	Stephen I. Katz MD PhD 1941â€™2019. British Journal of Dermatology, 2019, 180, 1268-1269.	1.5	0
13	Highâ€™dose intravenous immunoglobulin as adjuvant treatment for grade <scp>IV</scp> acute cutaneous graftâ€™versusâ€™host disease. British Journal of Dermatology, 2019, 181, 869-871.	1.5	4
14	Subacute cutaneous lupus erythematosus and dermatomyositis associated with antiâ€™programmed cell death 1 therapy. British Journal of Dermatology, 2019, 181, 580-583.	1.5	28
15	MON-218 Inflammatory Role of Sex Steroids in Hidradenitis Suppurativa: An Androgenic Phenotype. Journal of the Endocrine Society, 2019, 3, .	0.2	0
16	Eosinophils Mediate Tissue Injury in the Autoimmune Skin Disease Bullous Pemphigoid. Journal of Investigative Dermatology, 2018, 138, 1032-1043.	0.7	65
17	Noninvasive optical spectroscopy for identification of nonâ€™melanoma skin cancer: Pilot study. Lasers in Surgery and Medicine, 2018, 50, 246-252.	2.1	9
18	International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita. British Journal of Dermatology, 2018, 179, 30-41.	1.5	62

#	ARTICLE	IF	CITATIONS
19	Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis. PLoS ONE, 2018, 13, e0198074.	2.5	15
20	The SID Is 80 Years Old and Just Getting Started. Journal of Investigative Dermatology, 2017, 137, 1599-1600.	0.7	0
21	KIND1 Loss Sensitizes Keratinocytes to UV-Induced Inflammatory Response and DNA Damage. Journal of Investigative Dermatology, 2017, 137, 475-483.	0.7	7
22	Doxycycline and the treatment for bullous pemphigoid: what outcomes are most important to our patients?. British Journal of Dermatology, 2017, 177, 1145-1147.	1.5	1
23	Opportunistic cutaneous fungal infections in the inpatient setting. International Journal of Dermatology, 2016, 55, e223-6.	1.0	1
24	Use of Drawing Lithography-Fabricated Polyglycolic Acid Microneedles for Transdermal Delivery of Itraconazole to a Human Basal Cell Carcinoma Model Regenerated on Mice. Jom, 2016, 68, 1128-1133.	1.9	14
25	Redefining the roles of apoptotic factors in carcinogenesis. Molecular and Cellular Oncology, 2016, 3, e1054550.	0.7	7
26	Definitions and outcome measures for mucous membrane pemphigoid: Recommendations of an international panel of experts. Journal of the American Academy of Dermatology, 2015, 72, 168-174.	1.2	133
27	Caspase-3 Promotes Genetic Instability and Carcinogenesis. Molecular Cell, 2015, 58, 284-296.	9.7	202
28	Reshaping the treatment of autoimmune blistering diseases: from consensus guidelines to prospective data from "the crowd". British Journal of Dermatology, 2015, 172, 845-846.	1.5	0
29	A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. British Journal of Dermatology, 2015, 172, 760-768.	1.5	47
30	Rituximab decreases without preference all subclasses of IgG anti-BP180 autoantibodies in refractory bullous pemphigoid (BP). Journal of Dermatological Science, 2014, 74, 93-94.	1.9	13
31	Association of Serum B-Cell Activating Factor Level and Proportion of Memory and Transitional B Cells with Clinical Response after Rituximab Treatment of Bullous Pemphigoid Patients. Journal of Investigative Dermatology, 2013, 133, 2786-2788.	0.7	55
32	Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts. Journal of the American Academy of Dermatology, 2012, 66, 479-485.	1.2	294
33	Characterization of a rare IL-10 ^{hi} competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood, 2011, 117, 530-541.	1.4	969
34	Chronic Lymphocytic Leukemia Shares a Common Cellular Origin with Regulatory B10 Cells. Blood, 2011, 118, 286-286.	1.4	0
35	Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus. Journal of Investigative Dermatology, 2009, 129, 2404-2410.	0.7	183
36	Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. Journal of the American Academy of Dermatology, 2008, 58, 1043-1046.	1.2	464

#	ARTICLE	IF	CITATIONS
37	Serum IL-8 in Patients with Dermatitis Herpetiformis is Produced in Response to Dietary Gluten. <i>Journal of Investigative Dermatology</i> , 2007, 127, 2158-2165.	0.7	29
38	Cutaneous Endothelial Cell Activation in Normal Skin of Patients with Dermatitis Herpetiformis Associated with Increased Serum Levels of IL-8, sE-Selectin, and TNF- α . <i>Journal of Investigative Dermatology</i> , 2006, 126, 1331-1337.	0.7	38
39	A Prospective Clinical and Pathological Examination of Injection Site Reactions with the HIV-1 Fusion Inhibitor Enfuvirtide. <i>Antiviral Therapy</i> , 2006, 11, 935-940.	1.0	11
40	Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2002, 30, 327-329.	2.4	68
41	The 120-kDa soluble ectodomain of type XVII collagen is recognized by autoantibodies in patients with pemphigoid and linear IgA dermatosis. <i>British Journal of Dermatology</i> , 2000, 143, 104-111.	1.5	38